Pharma Regulatory Learning Hub

ICH Guidelines Quizzes

ICH Q1A(R2): Stability Testing Quiz

Scenario-based quiz for experienced professionals on ICH Q1A Stability Testing.

Quiz: ICH Q1A

1. What is the primary purpose of stability testing as defined by ICH Q1A?

To provide evidence on how the quality of a substance varies with time to establish shelf-life To define manufacturing process validation limits

2. For a drug intended for storage under general conditions, what are standard long-term testing conditions?

40°C ± 2°C / 75% RH ± 5% RH 25°C ± 2°C / 60% RH ± 5% RH or 30°C ± 2°C / 65% RH ± 5% RH

3. What is considered a "significant change" during accelerated stability testing?

A 5% loss in initial assay value or failure to meet appearance criteria A 1% increase in an identified impurity

4. Can you extrapolate the shelf-life beyond the period covered by real-time data at submission?

No, never. Yes, provided supporting accelerated data shows little degradation and variability

5. What is the required testing frequency for long-term stability studies mapping the first year?

Every 3 months Every 6 months

ICH Q1B: Photostability Testing Quiz

Scenario-based quiz for experienced professionals on ICH Q1B.

Read Guideline

Quiz: ICH Q1B

1. A drug substance shows degradation when exposed to light. What is the next step?

Conduct confirmatory photostability testing per Q1B Ignore since accelerated stability covers it

2. What is the minimum overall illumination standard for confirmatory photostability testing?

1.0 million lux hours Not less than 1.2 million lux hours and 200 watt hours/square meter

3. What presentation should be tested first during confirmatory photostability studies?

The fully exposed product The product directly in its immediate pack

4. If a fully exposed drug product is clearly photostable, is further testing required?

No, generally no further testing is required Yes, must test in the marketing pack

5. What chemical actinometric system is recommended for calibrating light sources?

0.1 N hydrochloric acid 2% w/v aqueous quinine monohydrochloride dihydrate

ICH Q2(R2): Analytical Validation

Test your knowledge on the foundational methodology of analytical validation.

Read Guideline

Quiz: ICH Q2(R2)

1. According to ICH Q2(R2), what are the four most common types of analytical procedures to be validated?

Identification, Quantitative tests for impurities, Limit tests for impurities, and Quantitative tests for the active moiety Identity, Dissolution, Content Uniformity, and Sterility

2. What does 'Specificity' refer to in ICH Q2(R2)?

The ability to elicit responses proportional to the concentration The ability to assess unequivocally the analyte in the presence of components expected to be present

3. For the validation of an assay of the active substance, what is the recommended minimum specified range?

From 80 to 120 percent of the test concentration From 50 to 150 percent of the test concentration

4. What is 'Robustness' as defined in Q2(R2)?

A measure of capacity to remain unaffected by small, deliberate variations in method parameters The degree of agreement among individual test results on repeated samplings

5. How is the Limit of Quantitation (LOQ) commonly determined by signal-to-noise ratio?

A signal-to-noise ratio of 3:1 A signal-to-noise ratio of 10:1

ICH Q2(R2) / Q14: Validation & Development

Test your knowledge on the combined modern approach to analytical procedure lifecycle.

Read Q2(R2)/Q14 Guide

Quiz: ICH Q2/Q14

1. How do ICH Q2(R2) and Q14 interact in the regulatory framework?

Q14 covers development and lifecycle management; Q2(R2) covers the actual validation They are mutually exclusive guidelines based on geographical regions

2. What is a key new addition in ICH Q2(R2) compared to older validation methods?

It eliminates specificity testing for HPLC It includes principles for the validation of multivariate analytical procedures (e.g., NIR, Raman)

3. Under the combined Q2/Q14 framework, what is the role of the Analytical Target Profile (ATP)?

It prospectively defines the performance criteria an analytical procedure must meet to be fit for purpose It is a historical record of all failed validation batches

4. What approach does Q14 endorse for modifying analytical procedures post-approval?

A structured lifecycle approach where predefined Established Conditions facilitate regulatory flexibility A strict rule that any change requires a new Marketing Authorization

5. When validating a multivariate procedure per Q2(R2), what additional aspect often requires validation?

The physical size and footprint of the spectrometer The robustness and validity of the underlying data model and calibration dataset over time

ICH Q3A(R2): Impurities in New Drug Substances

Test your knowledge on thresholds and safety aspects of impurities.

Read Guideline

Quiz: ICH Q3A

1. What does the ICH Q3A guideline specifically address?

Chemistry and safety aspects of impurities in new drug substances Impurities in biotechnological products

2. What governs the qualification threshold for impurities?

The route of administration The maximum daily dose of the new drug substance

3. What is the reporting threshold for a drug substance with a max daily dose <= 2g/day?

0.05% 0.10%

4. Which of the following is excluded from the scope of ICH Q3A?

Extraneous contaminants and polymorphic forms Organic impurities arising from manufacturing

5. What must be established to justify structural characterization limits?

Shelf-life limit Identification threshold

ICH Q3B(R2): Impurities in New Drug Products

Test your knowledge on degradation products and stability impacts.

Read Guideline

Quiz: ICH Q3B

1. What is the main focus of ICH Q3B?

Degradation products occurring in new drug products Impurities arising solely from excipients

2. How do reporting thresholds in Q3B compare to Q3A?

They are lower to ensure higher safety margins They are higher because of potential excipient interference and formulation complexity

3. If a degradation product is also a known metabolite of the drug substance:

Qualification may be considered already established It must undergo a full new qualification process

4. When should analytical procedures be validated for impurities?

Post-approval Before release testing and stability studies

5. Which degradation products need regular monitoring in the specifications?

Those consistently observed above the identification threshold Any degradation product, even those below the reporting threshold

ICH Q3C(R8): Residual Solvents

Test your knowledge on class limits and permitted daily exposures.

Read Guideline

Quiz: ICH Q3C

1. How are residual solvents classified in ICH Q3C?

By risk assessment into Classes 1, 2, and 3 based on toxicity By their boiling points into High, Medium, and Low

2. Class 1 solvents like benzene should:

Be limited by GMP and strictly controlled to below 50 ppm Be avoided unless strongly justified, due to unacceptable toxicities

3. What is the acceptable concentration limit for Class 3 solvents?

50 mg per day (equivalent to 5000 ppm) Based on Permitted Daily Exposure (PDE) calculations only

4. When calculating PDE, which modification factor accounts for human variability?

F2 F5

5. Is routine analytical testing required for Class 3 solvents?

Yes, for every batch regardless of concentration Not typically required if Loss on Drying is less than 0.5%

ICH Q3D(R2): Elemental Impurities

Test your knowledge on elemental toxicity limits and risk assessment.

Read Guideline

Quiz: ICH Q3D

1. What methodology does ICH Q3D advocate for controlling elemental impurities?

A risk-based approach evaluating toxicity and likelihood of presence Routine universal testing of all elements in every batch

2. Which elements belong to Class 1 due to high toxicity across all administration routes?

Platinum (Pt), Palladium (Pd), Ruthenium (Ru) Arsenic (As), Cadmium (Cd), Mercury (Hg), Lead (Pb)

3. If an elemental impurity's assessed level is consistently less than 30% of the PDE:

No additional controls are typically required A specification must still be set for the final drug product

4. What limits must be established when controlling elemental impurities?

Acceptable Daily Intakes (ADIs) based solely on body weight Permitted Daily Exposures (PDEs) based on route of administration

5. Do elemental impurities introduced intentionally as catalysts require evaluation?

Yes, they must be considered in the risk assessment No, if they are removed by generic purification steps

ICH Q3E: Extractables and Leachables

Test your scenario-based knowledge on analytical thresholds and E&L risks.

Read Guideline

Quiz: ICH Q3E

1. What is the primary purpose of the ICH Q3E concept?

To provide a framework for the assessment and control of extractables and leachables To mandate specific polymeric materials used in primary packaging universally

2. What differentiates "Extractables" from "Leachables" in the context of E&L studies?

Leachables are only found in solid oral dosage forms Extractables are generated under forced conditions; Leachables migrate under normal shelf-life conditions

3. Which is typically required for a high-risk dosage form (e.g., inhalation aerosols) regarding E&L?

Comprehensive extractables profiling followed by targeted leachables testing over shelf-life Only a compendial compliance check of the packaging materials

4. What concept bridges the safety assessment of Extractables to analytical thresholds?

Analytical Evaluation Threshold (AET) Overall Permitted Daily Exposure (PDE) combined limit

5. Are secondary packaging components considered in an E&L risk assessment?

No, secondary packaging never touches the product and poses no risk Yes, if there is a potential for migration via the primary packaging into the product

ICH Q6A: Chemical Substances Specifications

Test your knowledge on setting specifications for new chemical drug substances and products.

Read Guideline

Quiz: ICH Q6A

1. What is the fundamental definition of a "specification" according to ICH Q6A?

A list of tests, references to analytical procedures, and appropriate acceptance criteria A detailed description of the manufacturing process and process controls

2. What are the "universal tests" generally applicable to all new drug substances?

Description, Dissolution, Hardness, and Friability Description, Identification, Assay, and Impurities

3. For a solid oral drug product, when might testing for water content be necessary?

When the drug substance is hygroscopic or degrades heavily due to moisture Only when the product is formulated as a chewable tablet

4. Under Q6A, how should chiral drug substances generally be addressed in specifications?

An identity test should be capable of distinguishing both enantiomers and the assay should be enantioselective Enantiomeric purity is not required for specifications if the early synthesis is robust

5. Under Q6A, when is routine dissolution testing of solid oral dosage forms generally recommended?

It is only required for modified-release dosage forms, never for immediate release It is generally required for all solid oral dosage forms, though disintegration may sometimes be substituted

ICH Q6B: Biotechnological/Biological Products

Test your knowledge on specifications for biological and biotechnological products.

Read Guideline

Quiz: ICH Q6B

1. Why does ICH Q6B emphasize characterization so strongly compared to small molecules?

Because biotechnological products are highly complex and their quality cannot be fully established by end-product testing alone Because biotechnological products do not undergo clinical trials

2. What types of impurities are explicitly addressed in ICH Q6B?

Only inorganic elemental impurities such as heavy metals Product-related impurities and Process-related impurities (e.g. cell substrate, cell culture)

3. In Q6B, what is meant by "product-related substances"?

Variants of the desired product formed during manufacturing/storage that are active and have no deleterious effect Contaminants introduced accidentally during the fermentation step

4. Which of the following is typically required for characterizing a biological product under Q6B?

Physicochemical properties, biological activity, immunochemical properties, and purity Only molecular weight and boiling point

5. How is "Biological Activity" defined in Q6B specifications?

The half-life of the product once administered to the patient The specific ability or capacity of the product to achieve a defined biological effect

ICH Q14: Analytical Procedure Development

Test your expertise on enhanced lifecycle approaches for analytical methods.

Read Guideline

Quiz: ICH Q14

1. What is the core objective of the ICH Q14 guideline?

To harmonize scientific approaches for the development and lifecycle management of analytical procedures To completely replace the validation requirements found in ICH Q2

2. ICH Q14 frequently references the concept of ATP. What does ATP stand for?

Approved Testing Procedure Analytical Target Profile

3. What is the main benefit of using the "enhanced approach" for analytical procedure development under Q14?

Greater understanding and robustness, facilitating more flexible post-approval lifecycle management It exempts the procedure from carrying out formal validation activities

4. In the context of ICH Q14, what constitutes a "MODR"?

Method Operable Design Region, representing established operating conditions Minimum Observable Degradation Rate

5. How does risk assessment fit into analytical procedure development according to Q14?

It is only required if the procedure happens to fail the initial validation runs It is used continuously to identify and mitigate variables that could impact procedure performance